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Abstract 
Purpose: Sodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine 
phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line growth in 
vitro. We conducted a phase I clinical trial with SSG plus IFN-α in advanced cancer patients to 
assess tolerance, maximum tolerated dose (MTD) and immune system effects. 
Experimental Design: SSG was administered intravenously alone for five days of week 1, 
cycle 1 (21 days per cycle) and together with IFN-α 2b s (3 million units sc TIW) in week 2, 
and after a rest during week 3, on a 2-week on/1-week off cycle. SSG dose levels were 400, 
600, 900, 1125, and 1350 mg/m2.  
Results: Twenty-four patients were studied. Common toxicities included asymptomatic 
elevated serum lipase, thrombocytopenia, fatigue, fever, chills and anemia. The dose-limiting 
toxicities (DLT) were hypokalemia, thrombocytopenia, fatigue, pancreatitis and skin rash. The 
MTD was 900 mg/m2 SSG and IFN-α, 3 million units TIW. At this dose, patients had a sig-
nificantly lower number of regulatory T cells (TR Cells) (p = 0.012), myeloid dendritic cells 
(mDC) (p = 0.028); higher percentage of natural killer (NK) cells that synthesized perforin (p 
= 0.046) and of plasmacytoid dendritic cells (pDC) that secreted IFN-α (p = 0.018) in re-
sponse to activation through toll-like receptor (TLR) 7 and TLR 8 by CL097, the highly wa-
ter-soluble derivative of the imidazoquinoline compound R848.  
Conclusions: SSG in combination with IFN-α 2b was well tolerated and augmented cellular 
immune parameters. 
Key words: sodium stibogluconate, phase 1, interferon alpha, immunity, cancer 
INTRODUCTION 
Sodium stibogluconate (SSG), a small molecule 
inhibitor of protein tyrosine phosphatases (PTPases) 
[1], has been used extensively for the treatment of 
human leishmaniasis [2,3] and preclinically with de-
monstrable activity against a murine melanoma cell 
line [3]. SSG putatively interferes with SHP-1, so that 
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IFN-alpha (IFN-) remains in the “on” state and in-
hibits tumorigenesis [4]. IFN- 2b is FDA-approved 
for treating solid tumors such as malignant melanoma 
[5] and AIDS-related Kaposi’s sarcoma [6], and he-
matologic malignancies such as aggressive follicular 
non-Hodgkin’s lymphoma and chronic myelogenous 
leukemia [7]. However, tumor cell resistance and side 
effects often limit its clinical efficacy, which is ex-
pected to improve at a lower dose and when com-
bined with other therapeutic agents [8,9].  
The combination of SSG and IFN -2b was 
shown to be effective against larger WM9 tumors in 
mice and was well tolerated in a long-term treatment 
course [1]. These preclinical observations suggested an 
important potential for PTPase inhibitors to improve 
the efficacy of IFN -2b. Sodium stibogluconate is an 
ideal drug to evaluate as an antineoplastic agent in 
combination with IFN -2b. We hypothesized that 
combining SSG and IFN- 2b would modulate 
host-immune defense mechanisms and enhance anti-
tumor activity in cancer patients with tumors known 
to be responsive to IFN- therapy. Our goals in this 
phase I, dose-findin g study were to investigate the 
synergistic antitumor activity of the combination of 
SSG and IFN- 2b, delineate the toxicity profile, es-
tablish the maximum tolerated dose (MTD), and im-
mune effects in cancer patients.  
PATIENTS AND METHODS  
Patient eligibility and selection 
Inclusion criteria included metastatic or locally 
advanced solid cancers not responsive to conventional 
therapy with no established life-prolonging therapy 
available; age ≥18 years; Eastern Cooperative Oncol-
ogy Group (ECOG) (performance status 0–2; adequate 
bone marrow; adequate hepatic status, renal function 
(creatinine ≤1.5 mg/dL) and cardiac function (ejection 
fraction >50%); no chemotherapy or radiotherapy 3 
weeks before study entry. Exclusion criteria included 
concurrent immunotherapy, no recovery from acute 
toxicity of previous therapy, medically uncontrolled 
cardiovascular illness, electrocardiogram anomalies 
suggestive of cardiac conduction delay (QTc > 0.47 
seconds), past clinically significant cardiac arrhyth-
mias, symptomatic or untreated central nervous sys-
tem metastases and history of hypersensitivity to 
IFN-α 2b or SSG or their components.  
Treatment/study plan 
Sodium stibogluconate (Lenocta™) was supplied 
by VioQuest Pharmaceuticals, Inc. (Basking Ridge, 
NJ). Prior to enrollment, patients signed a written, 
informed consent in accordance with NCI require-
ments, the MD Anderson Cancer Center Institutional 
Review Board and the University of New Mexico 
(UNM) School of Medicine Human Research Review 
Committee policies.  
Cohorts of 3 patients each were enrolled using a 
standard phase I, 3+3 study design. Each cycle con-
sisted of 21 days. During the first week of cycle 1, pa-
tients received SSG alone intravenously (IV) over 15 
minutes for 5 days (Monday through Friday) (Figure 
1). In week 2, cycle 1, patients received SSG IV for 5 
days (Monday through Friday), along with 3x106 
units of IFN- 2b subcutaneously (SQ) three times a 
week (Monday, Wednesday, Friday). Week 3, cycle 1, 
was a rest period. During cycle 2 and subsequent cy-
cles, patients received SSG IV for 5 days and IFN- 2b 
SQ thrice weekly for the first and second weeks of 
each cycle. The SSG dose was escalated in successive 
cohorts, with no escalation within cohorts. Cycles 
continued until disease progression or dose-limiting 
toxicities(s) (DLT). 
 
 
 
Figure 1. Study design and treatment regimen. SSG 
was administered daily as a monotherapy during the first 
week of cycle 1. Peripheral blood samples were collected 
prior to therapy on the second week of cycle 1 (C1D8) to 
evaluate the effect of SSG. IFN-α 2b was administered 3 
times per week beginning the second week of cycle 1. 
Peripheral blood samples were collected at the end of 2 
cycles (C2D12) to evaluate the effect of SSG + IFN-α 2b 
combination therapy. 
 
 
Toxicity in each group of 3 patients treated with 
different dosage levels was graded according to the 
Common Terminology Criteria for Adverse Events 
(CTCAE), version 3.0, at the end of each cycle. Even 
though the traditional definition of DLTs within the 
first cycle was initially used, we later extended our 
DLT window to cycle 2 as the cycles were relatively 
short and only SSG was given during the first week of 
the first cycle. DLT was defined as any one or more of 
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the following events considered related to treatment 
with study drug that were grade >3: non-hematologic 
toxicity, grade 4 hematologic toxicity (neutropenia, 
anemia or thrombocytopenia), prolongation of QTc to 
>0.47 seconds, grade 2 or greater cardiovascular ar-
rhythmia, and/or ECG changes associated with T 
wave inversion with ST segment depression, any 
grade 4 pancreatic enzyme elevation that lasted long-
er than 8 days or that was accompanied by clinical 
symptoms of pancreatitis.  
A grade 3 non-hematologic toxicity or grade 4 
hematologic toxicity was considered a DLT only after 
delivery of maximum supportive care. Important 
medical events other than those listed above were 
considered a DLT based upon appropriate medical 
judgment and following discussion among the inves-
tigators and the VioQuest medical monitor. 
Dose escalation 
The starting dose of SSG was 400 mg/m2/day 
administered daily IV over 15 minutes. With no sig-
nificant toxicity, the dose for subsequent cohorts was 
increased by 50% of the preceding dose. If DLTs oc-
curred, the dose in subsequent cohorts was increased 
by only 25% of the preceding dose. Cohorts of at least 
3 patients were treated at each dose level until the 
MTD was defined. If 1 of 3 patients had a DLT, the 
cohort was expanded to a maximum of 6 patients. If 
only 1 of those 6 patients experienced a DLT, the dose 
for subsequent cohorts was escalated by 25%. If at 
least 2 patients in a cohort had DLTs, no dose escala-
tion was permitted. The dose level at which 2 of 6 
patients experienced a DLT was considered one dose 
level above the MTD. Table 1 shows the dose escala-
tion scheme for this study. 
 
Table 1: Dose Escalation Schedule for SSG and Fixed Dose 
of IFN- 2b (3 x 106 units) (N = 24 patients) 
Dose of SSG (mg/m2) N =  DLTs 
400  3 0 
600 5 0 
900 (expansion co-
hort) 
8 0 
1125 4 3 (symptomatic pancreatitis and 
thrombocytopenia) 
1350 4 2 (hypokalemia, thrombocytopenia, 
fatigue and skin rash) 
 
Duration of therapy 
Patients remained on protocol until disease pro-
gression, unacceptable adverse events, concurrent 
illness preventing further administration of drug, or if 
they had stable disease (SD), a partial response (PR), 
or a complete response (CR) to treatment, and if there 
was an acceptable toxicity profile. Patients were taken 
off study for therapy-related intolerable toxicity, pro-
gressive disease, or self-election to withdraw from 
study. 
Clinical response  
All patients underwent imaging with computed 
tomography (CT) scans and/or positron emission 
tomography (PET), and disease-specific tumor mark-
ers whenever applicable. Evaluation for treatment 
response was done every six weeks using Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria 
[10]. 
Immune monitoring of patients 
Patients were assessed prior to initiation of SSG 
therapy, cycle 1, day 1 (C1D1), at the end of SSG 
monotherapy (C1D5) and prior to addition of IFN- 
on C1D8, at the end of the combination therapy 
(C1D12), and on C2D12. On days of assessment, pa-
tients provided 27 mL of peripheral blood for immune 
evaluation that included leukocyte immunopheno-
typing, cytokine syntheses by individual T cells acti-
vated through the T-cell receptor (TCR) using an-
ti-CD3 antibodies and by toll-like receptor 
(TLR)-activated dendritic cells (DC); expression of 
granzyme B and perforin A by natural killer (NK), 
natural killer T (NKT) cells, and CD8+ T cells.  
Enumeration of leukocyte subsets by flow cy-
tometry  
Subsets of T cells (CD4, CD8, and T-regulatory 
(TR)), B-cells (CD19), and NK cells (CD56/16) cells 
were determined as previously described [11].  
Perforin A and Granzyme A expression by NK 
and NKT cells 
Briefly, peripheral blood lymphocytes were 
stained for cell surface markers CD3, CD16+56, and 
CD8 as previously described [11], then permeabilized 
with BD CytoFix/CytoPerm according to the manu-
facturer’s recommended procedures and stained with 
FITC conjugated antibodies against granzyme A, 
perforin or the appropriate isotype-matched control 
immunoglobin, and analyzed using 6-parameter flow 
cytometry. Perforin and granzyme expression was 
recorded as percentage of CD16/56+ (NK) or 
CD3+16/56+ (NKT) lymphocytes with fluorescent in-
tensity of the perforin or granzyme antibodies greater 
than isotype-matched control antibodies.  
Cytokine synthesis by anti-CD3 activated T cells  
Intracellular cytoplasmic interleukin (IL)-2, 
IL-10, interferon-gamma (IFN-), and tumor necrosis 
factor-alpha (TNF-) by TCR-activated T cells were 
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measured by a flow cytometric assay as previously 
described [12].  
Quantification of circulating DCs 
Subsets of myeloid DCs (mDC/DC1) and 
plasmacytoid DCs (pDC/DC2) were enumerated as 
previously reported [13].  
 
Cytokine synthesis by mDC and pDC activated 
through TLR 
Cytokine synthesis by DCs stimulated with 10 
µM of CL097, a highly water-soluble derivative of the 
imidazoquinoline compound R848 (Invivogen, San 
Diego, CA), was performed as previously described 
[14]. Similar to R848, CL097 is a TLR7 and TLR8 lig-
and that induces cytokine syntheses in DCs through 
the activation of the NF-κB [15,16].  
Statistical analysis 
Descriptive statistics were used for the patient 
treatment description. Due to small sample size and 
non-normal distribution of cytokine production, 
nonparametric tests compared median values for 
immunologic analysis. The Friedman test assessed 
significant rank differences in phenotype and cyto-
kine measures over the study period followed by the 
Wilcoxon signed-rank test of paired samples to de-
termine differences between specific time points in 
therapy. The Mann-Whitney U test analyzed differ-
ences among different treatment arms, i.e., low-dose 
SSG (<900 mg/m2) and high-dose (≥900 mg/m2). 
Graphs were plotted as mean plus or minus standard 
error to show central tendency and variance. 
RESULTS 
Patient characteristics 
Twenty-four patients (13 men and 11 women) 
participated in this phase I study (median age of 59.5 
years; range, 37-82). Nine patients had an ECOG per-
formance status of 0, and 15 patients had an ECOG of 
1. Prior therapies varied from 1 to 10 regimens (me-
dian, 4). Various solid tumors were included; most 
commonly melanoma, pancreatic and colorectal (Ta-
ble 2).  
Dose escalation and MTD 
Within the SSG 900 mg/m2 cohort, one patient 
progressed during cycle 1 and was replaced. Because 
three evaluable patients tolerated the 900 mg/m2 SSG 
dose, it was increased to 1350 mg/m2, and two pa-
tients experienced DLTs. The first patient with DLT 
had a grade 4 hypokalemia and a grade 4 thrombo-
cytopenia (which did not return to baseline after 
platelet transfusion). The second patient with DLT 
had grade 3 fatigue and grade 3 skin rash. Subse-
quently, an intermediate dose of SSG of 1125 mg/m2 
was tested. One patient in this cohort had a grade 2 
DLT of clinically symptomatic pancreatitis and the 
cohort was expanded. Two additional patients had 
grade 2 pancreatitis and grade 4 thrombocytopenia. 
Thus, the MTD was set at 900 mg/m2. The cohort was 
expanded to total of 8 patients. No DLTs were ob-
served. 
Table 2: Patient Characteristics (N = 24)  
Total Pts   24     
Median Age 59.5    
Range 37-82    
Male 13    
Female 11    
     
Race     
White 22    
Asian 1    
Hispanic 1    
     
ECOG     
PS= 0 9    
PS=1 15    
     
Media Prior Regimens 4    
Max 10    
Min 1    
     
Diagnosis Number % Dosage Patients 
 
Melanoma 
7 29 400 3 
Pancreatic 4 17 600 5 
Colorectal 3 13 900 8 
Adenocystic H&N 2 8 1125 4 
Mesothelioma 1 4 1350 4 
Prostate 1 4   
Neuroendrocrine 1 4 Total 24 
Ovarian 1 4   
Squamous Cell H&N 1 4   
Granulosa Cell 1 4   
Merkel Cell 1 4   
Angiosarcoma 1 4   
     
Total 24 99   
PS , performance status; ECOG, Eastern Cooperative Oncology 
Group; H&N, head and neck 
 
Safety/Toxicity 
Adverse events are shown in Table 3. Despite 
elevated serum amylase (n=7) and/or lipase (n=16) 
levels occurring frequently, most patients were 
asymptomatic; two had clinically significant grade 2 
pancreatitis. Fourteen patients completed two cycles 
and were restaged. One patient with advanced re-
fractory colorectal cancer in the 600 mg/m2 SSG co-
hort received cycle 3, but withdrew from the study. 
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The second patient with adenocystic carcinoma in the 
1350 mg /m2 SSG cohort, also with SD, withdrew 
from the study due to non-DLT side effects and 
treatment schedule. A third patient with ocular mel-
anoma in the 400 mg /m2 SSG cohort had SD after two 
cycles, but withdrew from treatment. The other 11 
patients had progressive disease at restaging at the 
end of cycle 2. Although there was no clinically ob-
servable anticancer activity in this study, SSG had 
significant effects on host-immune responses.  
Table 3: Drug Related Common Side Effects 
  Side Effects at Different Dose Levels 
 TOTAL DLTS 400 mg/m2 600 mg/m2 900 mg/m2 1125 mg/m2 1350 mg/m2 
Grade 1-2 3 4 1-2 3 4 1-2 3 4 1-2 3 4 1-2 3 4 1-2 3 4 
Nausea 6 0 0 1   1   2   1   1   
Vomiting 4 0 0 1      1   1   1   
Chills 9 1 0 2   4   1   1   1 1  
Fatigue 7 4 0 2 1  3   1 1   1  1 1  
Fever 10 1 0 1   5   2   1   1 1  
Myalgia 3 0 0    2         1   
Rash 1 1 0          1    1  
Anorexia 5 1 0    1   2 1  1   1   
Lymphopenia 4 0 0    4            
Leukocytes 4 1 0    1   1 1     2   
Neutrophils 5 0 0    1   2      2   
Platelets 3 5 3     1  3 1    2  3 1 
Hemoglobin 3 7 0  1     1 5     2 1  
Amylase 3 4 0 1   1 1  1 1   1   1  
Lipase 4 7 5   1 1 2 1 2 3 1   1 1 2 1 
Potassium, Serum Low 2 4 2       1 2 1  2  1  1 
Pancreatitis 2 0 0          2      
 
 
Enumeration of leukocyte subsets by flow cy-
tometry  
Seventeen patients were evaluated for immune 
studies. For the immunology data analysis, patients 
who received SSG <900 mg/m2 (n=8) were defined as 
the low-dose SSG cohort, and patients who received a 
dose of SSG ≥900 mg/m2 were defined the high-dose 
SSG cohort (n=9).  
Initially, the effect of SSG monotherapy, C1D1 
vs. C1D8, and the effect of SSG in combination with 
IFN- (C1D8 vs. C2D12) were assessed in all patients. 
After SSG monotherapy, median %TR cells (p = 0.022) 
(Figure 2), median %mDC (p = 0.003) (Figure 3A) and 
median %pDC (p = 0.022) (Figure 3B) significantly 
decreased, but following combination therapy median 
%mDC (p = 0.041) significantly increased (Figure 3A). 
In patients receiving low-dose SSG monotherapy, 
there were statistically significant reductions in the 
median %CD4+ T cells (43.7% vs. 41.1%, p = 0.036) and 
median %TR cells (2.5% vs. 2.0%, p = 0.017), but sta-
tistically significant increases in median %NK cells 
(17.6% vs. 22.3%, p =0.05). Following combination 
therapy the median %mDC increased (47.8% vs. 
58.3%, p = 0.028). However, in patients receiving 
high-dose SSG there were no statistically significant 
changes in median %CD4+ T (49.0% vs. 49.9%, p = 
0.575), median %TR cells (3.4% vs. 3.0%, p = 0.444), 
and median %NK cells (16.6% vs. 14.4%, p = 0.721). 
Following combination therapy the median %mDC 
increased in patients receiving low-dose SSG (47.8% 
vs. 58.3%, p = 0.028), and although there was a similar 
trend in patients receiving high-dose SSG, it was not 
statistically significant (45.0% vs. 55.0%, p = 0.893).  
 
Figure 2 Differences in the percentage of 
CD4+CD25hi TR cells. Fresh peripheral blood samples 
were evaluated by flow cytometry for the presence of 
CD3+CD4+CD25hi TR cells at baseline, following SSG 
monotherapy (C1D8), and following SSG + IFN-α 2b 
combination therapy (C2D12). There was a significant 
decrease in the percentage of CD3+CD4+CD25hi TR cells 
following SSG monotherapy. 
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Figure 3 Differences in the percentage of dendritic cells. Fresh peripheral blood samples were evaluated by flow 
cytometry for the presence of Lin-HLA-DR+ dendritic cells at baseline, following SSG monotherapy (C1D8) and following 
SSG + IFN-α combination therapy (C2D12). (A) Following SSG monotherapy, there was a transient decrease in the per-
centage of CD11c+CD123- mDC within the Lin-HLA-DR+ population followed by a significant increase with the addition of 
IFN-α 2b. (B) The percentage of CD11c-CD123+ pDC decrease within the Lin-HLA-DR+ DC population following SSG 
monotherapy.  
 
Figure 4 Differences in the percentage of NK and NKTcells that produced perforin A. Fresh peripheral blood 
samples were evaluated by flow cytometry for the presence of NK and NKT cells with constitutive perforin A. (A) Perforin 
expression by NK cells is unaffected by SSG monotherapy (C1D8). Following treatment with both SSG and IFN- α 2b 
(C2D12), there is a significant increase in the percentage of NK cells expressing perforin A. (B) Similarly in CD3+16/56+ 
NKT cells, perforin A expression was unaffected by SSG monotherapy but was significantly increased by treatment with both 
SSG and IFN-α 2b (C2D12). 
 
 
Cytokine production by TLR-activated mDC and 
pDC  
In all patients at the end of SSG monotherapy 
(C1D8) as well at the end of combination therapy 
(C2D12), there were no significant changes in %mDC 
and %pDC that synthesized cytokines following ac-
tivation with the TLR agonist CL097 (data not shown). 
However, patients who received high-dose SSG had 
statistically significant increased median %pDC that 
synthesized IFN- following activation through TLR7 
and TLR8 by CL097 (3.15% vs. 9.09%, p = 0.012). 
When IFN- 2b was added to this regimen, the per-
cent of pDC that produced IFN- increased further 
but not to statistical significance (9.09% vs. 12.98%, p = 
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0.0465). The syntheses of IL-10, IL-12, and TNF- by 
TLR-activated mDC remained unchanged with 
high-dose SSG monotherapy or following combina-
tion therapy of high-dose SSG and IFN- 2b in both 
dose groups. Similarly, SSG alone or in combination 
with IFN- 2b did not affect the ability of 
TCR-activated CD4+ T and CD8+ T cells to synthesize 
cytokines.  
Expression of granzyme B and perforin A by NK, 
NKT, and CD8+ T cells 
NK, NKT and CD8+ T cells mediate tumor cell 
cytotoxicity through expression of granzyme B and 
perforin A. Data on all patients show that SSG alone 
did not affect the expression of perforin A and 
granzyme B in NK, NKT, and CD8+ T cells. Following 
the addition of IFN- 2b, there was a statistically sig-
nificant increase in median %NK cells (62.4% vs. 
68.8%, p = 0.038) (Figure 4A) and median %NKT cells 
(7.4% vs. 18.0%, p = 0.006) (Figure 4B), but not in me-
dian CD8+ T cells expressing perforin A. Patients re-
ceiving high-dose SSG and IFN- 2b had a higher 
%NK cells expressing perforin A (66.5% vs. 75.6%, p = 
0.028). No differences were observed in expression of 
granzyme B by NK, NKT, and CD8+ T cells of patients 
at either dose of SSG.  
DISCUSSION 
This phase I study investigated the biological 
activity of SSG in combination with IFN- 2b to de-
termine toxicity profile, MTD, and immune system 
effects. All patients had multiple prior treatments. No 
clinical responses were observed, despite the known 
biological activity of SSG in a number of animal ex-
perimental systems [17] where SSG alone or in com-
bination with IFN- 2b, demonstrated antitumor ac-
tivity against prostate cancer xenografts [18]. In an-
other experiment of SSG plus IL-2, antitumor activity 
against renal cell carcinoma in mice was enhanced 
and mediated through an immune mechanism in-
volving IFN- [19].  
Common toxicities included asymptomatic ele-
vated serum lipase, thrombocytopenia, fatigue, fever, 
chills and anemia. The DLT were hypokalemia, 
thrombocytopenia, fatigue, pancreatitis and skin rash. 
Patients who received high-dose SSG had a sta-
tistically significant decrease in the median percent-
age of pDC at the end of SSG monotherapy with a 
concomitant statistically significant increase in the 
median percentage of pDC that produced IFN-. At 
the end of cycle 2, day 12, the median percentages of 
pDC and pDC producing IFN- were increased. 
Plasmacytoid dendritic cells are the most potent 
producers of IFN- [20-22]. They greatly influence the 
differentiation of CD4+ T cells towards TH2 responses 
by producing IL-10 and inhibiting the production of 
IL-12 by mDC [23], or enhancing the development of 
TR cells, which, in turn, suppresses antigen-specific 
immune responses [24]. Conversely, IL-12 production 
by mDC enhances IFN- produced by T cells and NK 
cells and favors a TH1 immune response [25]. Here, 
low-dose SSG increased pDC activity as measured by 
the increased median percentage of TLR-activated 
pDC that produced IFN-.  
IFN- also stimulates mDC to stimulate IL-12, 
which in turn stimulates T-cells to secrete IFN-, and 
arms NK cells and CD8+ cytotoxic T lymphocytes 
(CTL) with perforin A and granzyme B for killing 
tumor targets. However, increased production of 
IFN- by pDC after SSG monotherapy were insuffi-
cient to induce expression of perforin A by NK or 
NKT cells. Only after IFN- 2b administration did the 
median percentages of NK cells and NKT cells that 
expressed perforin A increase. Thus, the combination 
of SSG and IFN- 2b was necessary to induce expres-
sion of perforin A by these innate immune cells.  
Whereas NK cell activity is associated with in-
nate immunity, CD8+ CTL is required for adaptive 
immunity. Sustained adaptive immunity depends 
upon the production of IL-2 by activated CD4+ T cells 
to sustain T-cell proliferation and the production of 
IFN- by activated macrophages to co-stimulate CD8+ 
CTL. As TR cells inhibit the production of IL-2 by ac-
tivated T cells [26], the reduction in TR activity is de-
sirable for an adequate antitumor response. In the 
current study, administration of low-dose and 
high-dose SSG alone yielded significantly lower per-
centages of TR cells. However, IL-2 production by 
TCR-activated T cells was observed only in patients 
receiving high-dose SSG, and only after adding IFN- 
2b. Activation of TR cells inhibits production of IL-2 by 
activated T cells [26]. Although we did not measure 
circulating levels of IFN-, we measured IL-12 pro-
duced by mDC following activation through the TLR. 
IL-12 is responsible for inducing IFN- by T cells and 
NK cells [25]. Unfortunately, SSG alone and in com-
bination with IFN- 2b failed to significantly augment 
the percentage of TLR-activated mDC that produced 
IL-12. This may account for the lack of IFN- produc-
tion by T cells and the resultant lack of antitumor ac-
tivity in our patients. Others reported increases in 
plasma levels of IFN- and in the percentage of CD4+ 
T cells that were capable of producing IFN- [27] as 
well as increased IFN- mRNA expression by alveolar 
macrophages following SSG administration [28] in 
mice.  
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This study was limited by the lack of a cohort 
that received IFN- 2b prior to SSG, which would 
have permitted comparing IFN- 2b and SSG as sin-
gle agents, thereby helping to determine the optimal 
immune modulatory effect of these two drugs. This 
was not done because of limitations inherent in a 
phase I study.  
In conclusion, SSG in combination with IFN- 2b 
was well tolerated at 900 mg/m2 and demonstrated 
immune modulation. There was an increase in the 
proportion of TLR7- and TLR8-activated pDC in pa-
tients receiving high-dose SSG that produced IFN-. 
These data represent increased adaptive and innate 
immune responses following therapy with high-dose 
SSG in combination with IFN- 2b. 
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